-
A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
NCT07458347 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Utah: Salt Lake City
-
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
NCT07020221 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Utah: Salt Lake City
-
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
NCT07644559 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Utah: West Valley City
-
A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations
NCT06906562 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Utah: Cedar City, Salt Lake City
-
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
NCT06244771 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Utah: West Valley City
-
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
NCT04657068 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Utah: Salt Lake City
-
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
NCT07488676 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Utah: West Valley City
-
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
NCT07277413 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Utah: West Valley City
-
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
NCT06465069 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Utah: Salt Lake City, West Valley City
-
A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
NCT06400472 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Utah: West Valley City
-
A Study of MGC026 in Participants With Advanced Solid Tumors
NCT06242470 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Utah: West Valley City
-
A Study of MGC028 in Participants With Advanced Solid Tumors
NCT06723236 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Utah: West Valley City
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
NCT05208762 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Utah: West Valley City
-
A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors
NCT07300150 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Utah: West Valley City
-
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
NCT07522073 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Utah: Salt Lake City
-
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
NCT07409272 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Utah: Salt Lake City
-
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
NCT06330064 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Utah: Salt Lake City
-
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
NCT07223047 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Utah: West Valley City
-
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
NCT04858334 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Utah: Farmington, Salt Lake City
-
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
NCT06917079 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Utah: Salt Lake City
-
Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen
NCT07087054 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Utah: Salt Lake City
-
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
NCT05297734 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Utah: Salt Lake City
-
Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers
NCT04239573 ·
Phase: Not specified ·
Ages: 50 Years to 75 Years ·
Sex: All (male and female)
· Utah: Salt Lake City
-
Increasing Germline Genetic Testing for Patients With Cancer
NCT07307664 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: No age limits stated ·
Sex: All (male and female)
· Utah: Salt Lake City
-
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
NCT06973564 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Utah: Salt Lake City
-
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
NCT06586515 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Utah: Salt Lake City
-
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
NCT05059444 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Utah: Salt Lake City
-
Pancreatic Cancer Early Detection Consortium
NCT04970056 ·
Phase: Not specified ·
Ages: 18 Years to 90 Years ·
Sex: All (male and female)
· Utah: Salt Lake City, St. George
-
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
NCT07145255 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Utah: West Valley City
-
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
NCT03452774 ·
Phase: Not specified ·
Ages: No age limits stated ·
Sex: All (male and female)
· Utah: Salt Lake City
-
Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
NCT05732831 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Utah: Salt Lake City
-
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
NCT07030257 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Utah: West Valley City
-
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
NCT07252232 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Utah: Salt Lake City
-
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
NCT07491445 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Utah: Salt Lake City
-
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
NCT06445062 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Utah: Salt Lake City
-
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
NCT05379985 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Utah: Salt Lake City
-
Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
NCT05477576 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Utah: Salt Lake City
-
Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.
NCT07165132 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Utah: Salt Lake City
-
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
NCT05005403 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Utah: West Valley City
-
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
NCT05985655 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Utah: West Valley City
-
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
NCT06922591 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Utah: Salt Lake City
-
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
NCT04172532 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Utah: Salt Lake City
-
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
NCT05040360 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Utah: Farmington, Salt Lake City
-
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
NCT03556228 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 80 Years ·
Sex: All (male and female)
· Utah: Salt Lake City
-
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
NCT06943755 ·
Phase: Phase 2, Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Utah: Salt Lake City